---
title: Ex Vivo Cancer Drug Screening Platform (EVIDENT)
summary: Developed a high-content ex vivo solid tumour biosample processing and drug efficacy screening platform using 2D/3D cell culture models, fluorescence and spatial imaging, and machine learning â€” to enable personalised cancer therapy selection for solid tumours including melanoma.
tags:
  - Oncology
  - Machine Learning
  - Drug Screening
  - Clinical Research
  - UK
date: 2021-10-01

# Optional external URL for project (replaces project detail page).
external_link: ''

image:
  caption: EVIDENT Project â€” University of Sheffield
  focal_point: Smart

links:
  - icon: book
    icon_pack: fas
    name: Publication (2024)
    url: https://www.tandfonline.com/doi/full/10.1080/1744666X.2024.2336583
  - icon: book-open
    icon_pack: fas
    name: ESMO 2023 Abstract
    url: https://doi.org/10.1016/j.annonc.2023.09.1329
  - icon: university
    icon_pack: fas
    name: University of Sheffield
    url: https://www.sheffield.ac.uk
---

## Overview

The **EVIDENT** (Ex Vivo Determined Cancer Therapy) project, funded by the Commonwealth PhD Scholarship (Â£158,685) and a UKRI Knowledge Exchange Fund grant (Â£10,890.67), developed a comprehensive ex vivo drug efficacy screening platform for solid cancers â€” with a primary focus on melanoma. The platform integrates biosample processing, 2D and 3D tumour spheroid culture, high-content imaging, and machine learning to predict individual patient responses to targeted and immune therapies.

## Key Activities

- **Platform Development** â€” Developed end-to-end SOPs for solid tumour biosample collection, thermal chain maintenance, ex vivo processing, drug application, data recording, and long-term liquid nitrogen storage; mock runs and QC protocols implemented throughout
- **2D & 3D Cell Culture Models** â€” Established and optimised conventional monolayer and patient-derived tumour spheroid/3D co-culture systems; resolved early challenges in spheroid formation through collaboration with Misvik Biology (Finland) and Nanobug-Oncology (Sheffield), and by conducting targeted literature review
- **High-Content Imaging & Spatial Analysis** â€” Applied fluorescence microscopy and spatial imaging to quantify cell viability, morphology, and drug response across multiple assay conditions; used Biorender for graphical abstracts and illustrations
- **Machine Learning for Image Analysis** â€” Trained a VGG19-based deep neural network for automated classification of biological imaging data; developed image analysis protocols in collaboration with Dr. Jamie Adams (UoS)
- **Multivariate Statistical Modelling** â€” Conducted multivariate analysis on observational clinical and experimental data to identify predictors of drug response; completed multiple R analysis courses to support statistical work
- **Knowledge Exchange & Grant Writing** â€” Wrote and secured a competitive UKRI Knowledge Exchange Fund grant application; gained experience in academia-enterprise collaboration, intellectual property rights, and commercialisation principles

## Conferences & Presentations

| # | Conference | Date | Location | Type |
|---|---|---|---|---|
| 1 | UoS Medical School Research Meeting 2022 | Jun 2022 | Sheffield, UK | ğŸª§ Poster |
| 2 | Melanoma Focus Virtual Regional Meeting | May 2023 | Virtual | ğŸª§ Poster |
| 3 | BACR Trailblazers in Cancer Research: The Next Generation | Jun 2023 | Manchester, UK | ğŸª§ Poster |
| 4 | Medical School PGR Symposium 2023 | Jul 2023 | Sheffield, UK | ğŸª§ Poster |
| 5 | BACR Tumour Microenvironment & 3D Model Workshop | Jul 2023 | Nottingham, UK | ğŸª§ Poster |
| 6 | ESMO Congress 2023 | Oct 2023 | Madrid, Spain ğŸ‡ªğŸ‡¸ | ğŸª§ Poster |
| 7 | Commonwealth Scholarship Commission PhD Conference | Jun 2024 | Windsor, UK | ğŸ¤ Oral |
| 8 | SMPH Annual Research Meeting 2024 | Jun 2024 | Sheffield, UK | ğŸ¤ Oral |
| 9 | 10th Annual Saskatchewan Cancer Research Conference | Jun 2025 | Saskatoon, Canada ğŸ‡¨ğŸ‡¦ | ğŸª§ Poster |

## Research Collaborations

| Partner | Type | Outcome |
|---|---|---|
| **Misvik Biology**, Turku, Finland ğŸ‡«ğŸ‡® | Biotech SME | Hands-on 3D culture training; secured UKRI KE Fund |
| **Nanobug-Oncology**, Division of Clinical Medicine, UoS | Research Group | 3D cell culture assay co-development |
| **Dr. Chun Guo's group**, School of Bioscience, UoS | Research Group | Co-authored publication (*Cell Death & Disease*, 2024) |
| **Dr. Gareth Richards' group**, Division of Clinical Medicine, UoS | Research Group | Novel compound efficacy assessment |

## Outputs & Awards

- ğŸ† **BACR/AstraZeneca Student Award** (2023) â€” Travel grant, ESMO Congress, Madrid
- ğŸ† **UKRI Knowledge Exchange Fund** (2023) â€” Â£10,890.67, EVIDENT melanoma feasibility
- ğŸ† **Commonwealth PhD Scholarship** â€” Â£158,685 (2021â€“2025)

## Publications

| | Title | Journal | Year |
|---|---|---|---|
| âœ… Published | [In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalised cancer therapy](https://doi.org/10.1080/1744666X.2024.2336583) | *Expert Review of Clinical Immunology* | 2024 |
| âœ… Published | [2302P Efficacy assessment of targeted and immunotherapies for melanoma using 2D and 3D ex-vivo assays](https://doi.org/10.1016/j.annonc.2023.09.1329) | *Annals of Oncology* (ESMO 2023) | 2023 |
| âœ… Published | [SENP3-FIS1 axis promotes mitophagy and cell survival under hypoxia](https://doi.org/10.1038/s41419-024-07271-8) | *Cell Death & Disease* | 2024 |
| ğŸ“ Under Review | Optimising spheroid formation and 3D co-culture assay for precision immunotherapy in solid cancers | *Frontiers in Immunology* | 2024 |

## Tools & Methods

`Python` Â· `R` Â· `VGG19 Deep Learning` Â· `High-Content Imaging` Â· `Spatial Transcriptomics` Â· `3D Tumour Spheroids` Â· `Drug Screening Assays` Â· `Multivariate Statistics` Â· `SOPs & GLP` Â· `Biorender`
